View Item 

Show simple item record

Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose
dc.contributor.authorHarder, Jennifer L.en_US
dc.contributor.authorHeung, Michaelen_US
dc.contributor.authorVilay, A. Maryen_US
dc.contributor.authorMueller, Bruce A.en_US
dc.contributor.authorSegal, Jonathan H.en_US
dc.date.accessioned2011-11-10T15:34:40Z
dc.date.available2012-09-04T15:27:38Zen_US
dc.date.issued2011-07en_US
dc.identifier.citationHarder, Jennifer L. ; Heung, Michael ; Vilay, A. Mary ; Mueller, Bruce A. ; Segal, Jonathan H. (2011). "Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose." Hemodialysis International 15(3). <http://hdl.handle.net/2027.42/86953>en_US
dc.identifier.issn1492-7535en_US
dc.identifier.issn1542-4758en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/86953
dc.description.abstractHemodialysis (HD) and continuous venovenous hemodialysis (CVVHD) have an unproven role in the management of carbamazepine overdose. Albumin‐enhanced CVVHD may accelerate carbamazepine (CBZ) clearance, but no pharmacokinetic data has been reported for traditional CVVHD without albumin enhancement. In addition, it is unclear whether the active CBZ‐epoxide metabolite is removed with either mode of dialysis. We present a case of CBZ intoxication successfully managed with sequential HD and CVVHD. The CBZ half‐life during CVVHD was 14.7 hours, compared with the patient's endogenous half‐life of 30.8 hours. The CBZ‐epoxide half‐life was 3.2 hours during HD. We conclude that HD and CVVHD provide effective clearance of CBZ and the epoxide metabolite and should be considered in the management of an acute toxic ingestion.en_US
dc.publisherBlackwell Publishing Incen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherCVVHDen_US
dc.subject.otherOverdoseen_US
dc.subject.otherPharmacokineticsen_US
dc.subject.otherCarbamazepineen_US
dc.subject.otherHemodialysisen_US
dc.titleCarbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdoseen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Nephrology, University of Michigan School of Medicine, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumClinical, Social & Administrative Sciences Department, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationotherDepartment of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USAen_US
dc.identifier.pmid21676154en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/86953/1/j.1542-4758.2011.00563.x.pdf
dc.identifier.doi10.1111/j.1542-4758.2011.00563.xen_US
dc.identifier.sourceHemodialysis Internationalen_US
dc.identifier.citedreferenceSchmidt S, Schmitz‐Buhl M. Signs and symptoms of carbamazepine overdose. J Neurol. 1995; 242: 169 – 173.en_US
dc.identifier.citedreferenceGraudins A, Peden G, Dowsett RP. Massive overdose with controlled‐release carbamazepine resulting in delayed peak serum concentrations and life‐threatening toxicity. Emerg Med. 2002; 14: 89 – 94.en_US
dc.identifier.citedreferenceVree TB, Janssen TJ, Hekster YA, Termond EF, van de Dries AC, Wijnands WJ. Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose. Ther Drug Monit. 1986; 8: 297 – 304.en_US
dc.identifier.citedreferenceAskenazi DJ, Goldstein SL, Chang IF, Elenberg E, Feig DI. Management of a severe carbamazepine overdose using albumin‐enhanced continuous venovenous hemodialysis. Pediatrics. 2004; 113: 406 – 409.en_US
dc.identifier.citedreferenceBek K, Kocak S, Ozkaya O, Yilmaz Y, Aydin OF, Tasdoven CS. Carbamazepine poisoning managed with haemodialysis and haemoperfusion in three adolescents. Nephrology. 2007; 12: 33 – 35.en_US
dc.identifier.citedreferenceHolubek WJ, Hoffman RS, Goldfarb DS, Nelson LS. Use of hemodialysis and hemoperfusion in poisoned patients. Kidney Int. 2008; 74: 1327 – 1334.en_US
dc.identifier.citedreferenceLow CL, Haqqie SS, Desai R, Bailie GR. Treatment of acute carbamazepine poisoning by hemoperfusion. Am J Emerg Med. 1996; 14: 540 – 541.en_US
dc.identifier.citedreferenceKielstein JT, Schwarz A, Arnavaz A, Sehlberg O, Emrich HM, Fliser D. High‐flux hemodialysis – an effective alternative to hemoperfusion in the treatment of carbamazepine intoxication. Clin Nephrol. 2002; 57: 484 – 486.en_US
dc.identifier.citedreferenceTapolyai M, Campbell M, Dailey K, Udvari‐Nagy S. Hemodialysis is as effective as hemoperfusion for drug removal in carbamazepine poisoning. Nephron. 2002; 90: 213 – 215.en_US
dc.identifier.citedreferenceSwartz R, Pasko D, O'Toole J, Starmann B. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol. 2004; 61: 134 – 143.en_US
dc.identifier.citedreferenceEichelbaum M, Ekbom K, Bertilsson L, Ringberger VA, Rane A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol. 1975; 8: 337 – 341.en_US
dc.identifier.citedreferenceGidal BE, Spencer NW, Maly MM, Pitterle ME. Evaluation of carbamazepine and carbamazepine‐epoxide protein binding in patients undergoing epilepsy surgery. Epilepsia. 1996; 37: 381 – 385.en_US
dc.identifier.citedreferenceHooper WD, King AR, Patterson M, Dickinson RG, Eadie MJ. Simultaneous plasma carbamazepine and carbamazepine‐epoxide concentrations in pharmacokinetic and bioavailability studies. Ther Drug Monit. 1985; 7: 36 – 40.en_US
dc.identifier.citedreferencePotter JM, Donnelly A. Carbamazepine‐10,11‐epoxide in therapeutic drug monitoring. Ther Drug Monit. 1998; 20: 652 – 657.en_US
dc.identifier.citedreferenceRambeck B, Salke‐Treumann A, May T, Boenigk HE. Valproic acid‐induced carbamazepine‐10,11‐epoxide toxicity in children and adolescents. Eur Neurol. 1990; 30: 79 – 83.en_US
dc.identifier.citedreferenceSo EL, Ruggles KH, Cascino GD, Ahmann PA, Weatherford KW. Seizure exacerbation and status epilepticus related to carbamazepine‐10,11‐epoxide. Ann Neurol. 1994; 35: 743 – 746.en_US
dc.identifier.citedreferenceCotter LM, Eadie MJ, Hooper WD, Lander CM, Smith GA, Tyrer JH. The pharmacokinetics of carbamazepine. Eur J Clin Pharmacol. 1977; 12: 451 – 456.en_US
dc.identifier.citedreferenceKonsil J, Dechasathian S, Mason DH Jr, Stevens RE. Reanalysis of carbamazepine and carbamazepine‐epoxide pharmacokinetics after multiple dosing of extended release formulation. J Pharm Pharm Sci. 2002; 5: 169 – 175.en_US
dc.identifier.citedreferenceChurchwell MD, Pasko DA, Smoyer WE, Mueller BA. Enhanced clearance of highly protein‐bound drugs by albumin‐supplemented dialysate during modeled continuous hemodialysis. Nephrol Dial Transplant. 2009; 24: 231 – 238.en_US
dc.identifier.citedreferenceDhondt A, Verstraete A, Vandewoude K, et al. Efficiency of the Genius batch hemodialysis system with low serum solute concentrations: The case of lithium intoxication therapy. Am J Kidney Dis. 2005; 46: e95 – e99.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1542-4758.2011.00563.x.pdf
Size:
91.26KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.